BR112012001258A2 - 1h-quinazolina-2,4-dionas para uso no tratamento da lipofuscinose ceroide neuronal - Google Patents
1h-quinazolina-2,4-dionas para uso no tratamento da lipofuscinose ceroide neuronalInfo
- Publication number
- BR112012001258A2 BR112012001258A2 BR112012001258A BR112012001258A BR112012001258A2 BR 112012001258 A2 BR112012001258 A2 BR 112012001258A2 BR 112012001258 A BR112012001258 A BR 112012001258A BR 112012001258 A BR112012001258 A BR 112012001258A BR 112012001258 A2 BR112012001258 A2 BR 112012001258A2
- Authority
- BR
- Brazil
- Prior art keywords
- diones
- quinazoline
- treatment
- neuronal ceroid
- ceroid lipofuscinosis
- Prior art date
Links
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical class C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 title 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 title 1
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22794009P | 2009-07-23 | 2009-07-23 | |
| PCT/EP2010/060733 WO2011009951A1 (en) | 2009-07-23 | 2010-07-23 | 1h-quinazoline-2, 4 -diones for use in the treatment of neuronal ceroid lipofuscinosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012001258A2 true BR112012001258A2 (pt) | 2016-02-10 |
Family
ID=42671655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012001258A BR112012001258A2 (pt) | 2009-07-23 | 2010-07-23 | 1h-quinazolina-2,4-dionas para uso no tratamento da lipofuscinose ceroide neuronal |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120122903A1 (enExample) |
| EP (1) | EP2456442A1 (enExample) |
| JP (1) | JP2012533605A (enExample) |
| KR (1) | KR20120052341A (enExample) |
| CN (1) | CN102470137A (enExample) |
| AU (1) | AU2010274921B2 (enExample) |
| BR (1) | BR112012001258A2 (enExample) |
| CA (1) | CA2768333A1 (enExample) |
| IN (1) | IN2012DN00235A (enExample) |
| MX (1) | MX2012000956A (enExample) |
| RU (1) | RU2012106426A (enExample) |
| WO (1) | WO2011009951A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5976011B2 (ja) * | 2011-04-05 | 2016-08-23 | 武田薬品工業株式会社 | スルホンアミド誘導体およびその用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9400680D0 (en) * | 1994-01-14 | 1994-03-09 | Sandoz Ltd | Improvements in or relating to organic compounds |
| GB0416730D0 (en) * | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
| GB0507298D0 (en) * | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
-
2010
- 2010-07-23 IN IN235DEN2012 patent/IN2012DN00235A/en unknown
- 2010-07-23 AU AU2010274921A patent/AU2010274921B2/en not_active Expired - Fee Related
- 2010-07-23 EP EP10734746A patent/EP2456442A1/en not_active Withdrawn
- 2010-07-23 US US13/384,280 patent/US20120122903A1/en not_active Abandoned
- 2010-07-23 KR KR1020127004575A patent/KR20120052341A/ko not_active Withdrawn
- 2010-07-23 RU RU2012106426/04A patent/RU2012106426A/ru not_active Application Discontinuation
- 2010-07-23 WO PCT/EP2010/060733 patent/WO2011009951A1/en not_active Ceased
- 2010-07-23 CA CA2768333A patent/CA2768333A1/en not_active Abandoned
- 2010-07-23 JP JP2012521055A patent/JP2012533605A/ja active Pending
- 2010-07-23 BR BR112012001258A patent/BR112012001258A2/pt not_active IP Right Cessation
- 2010-07-23 MX MX2012000956A patent/MX2012000956A/es not_active Application Discontinuation
- 2010-07-23 CN CN2010800334750A patent/CN102470137A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN00235A (enExample) | 2015-05-01 |
| EP2456442A1 (en) | 2012-05-30 |
| RU2012106426A (ru) | 2013-08-27 |
| JP2012533605A (ja) | 2012-12-27 |
| CN102470137A (zh) | 2012-05-23 |
| WO2011009951A1 (en) | 2011-01-27 |
| KR20120052341A (ko) | 2012-05-23 |
| AU2010274921A1 (en) | 2012-02-02 |
| US20120122903A1 (en) | 2012-05-17 |
| AU2010274921B2 (en) | 2014-08-14 |
| CA2768333A1 (en) | 2011-01-27 |
| MX2012000956A (es) | 2012-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1013698A2 (pt) | métodos para tratamento com o uso de terapia de combinação | |
| BR112012004281A2 (pt) | uso de metformina tratamento e prevenção de câncer | |
| BRPI0910259A2 (pt) | métodos de tratamento de inflamação | |
| BRPI1011916A2 (pt) | uso de uma combinação de filtro uv, e, preparação cosmética. | |
| PT2323642E (pt) | Utilização de edta+trometamina ou de fotoiativadores, associados a riboflavina para reticulação da córnea no tratamento de ceratocone ou de outros distúrbios ectásicos da córnea | |
| BRPI1016199A2 (pt) | cobertura de ferimento e kit de tratamento de ferimentos. | |
| BR112015001712A2 (pt) | uso de s-pindolol para o tratamento da caquexia e sarcopenia | |
| PL2200600T3 (pl) | Nerameksan do zastosowania w leczeniu podostrego szumu usznego | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| BR112012001797A2 (pt) | composto bicíclico e uso do mesmo para propósitos médicos | |
| BR112012000502A2 (pt) | terapia de combinação para o tratamento de diabetes | |
| BRPI0912687A2 (pt) | uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia | |
| BR112012001344A2 (pt) | derivados de 17hidróxi-17-pentafluoroetil-estra-4,9(10)-dieno-11-arila, método de produção destes e uso destes para o tratamento de doenças | |
| BR112012003372A2 (pt) | vitamina d3 e análogos da mesma para o tratamento de alopecia. | |
| BRPI1007995A2 (pt) | orto-aminoamidas para o tratamento de cãncer. | |
| BRPI0909818A2 (pt) | métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos | |
| BRPI0910780A2 (pt) | uso de antagonistas de opióides para o tratamento da retenção urinária | |
| BRPI1009448A2 (pt) | combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos | |
| BR112012030927A2 (pt) | fosfaplatinas e seu uso para o tratamento de cânceres | |
| BRPI0915905A2 (pt) | uso de derivados de pirimidilaminobenzamida para o tratamento de fibrose | |
| BRPI0907956A2 (pt) | Uso de ranolazina para o tratamento de doenças cardiovasculares | |
| BRPI0909096A2 (pt) | uso de conjugados de interleicna-1 no tratamento de diabetes | |
| PT3133396T (pt) | Métodos de tratamento utilizando fármacos eliminadores de amoníaco | |
| BRPI0918726A2 (pt) | derivados de 1-amino-alquilciclohexano para o tratamento de deficiência cognitiva em tinido | |
| BR112012002267A2 (pt) | compostos para o tratamento de inflamação. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |